Table 2 Subsequent treatment for patients treated with 1 L palbociclib + AI versus AI alone

From: Real-world effectiveness of palbociclib plus an aromatase inhibitor in HR+/HER2− MBC patients living in disadvantaged neighborhoods

Subsequent treatment, n (%)

Unadjusted

sIPTW

PSM

1 L PAL + AI (n = 394)

1 L AI alone (n = 329)

1 L PAL + AI (n = 405)

1 L AI alone (n = 324)

1 L PAL + AI (n = 186)

1 L AI alone (n = 186)

All treatments

177 (44.9)

235 (71.4)

192 (47.4)

236 (72.8)

82 (44.1)

128 (68.8)

 CDK4/6 inhibitor

77 (19.5)

120 (36.5)

77 (19.0)

123 (38.0)

33 (17.7)

73 (39.3)

 Chemotherapy

36 (9.1)

29 (8.8)

35 (8.6)

29 (8.9)

18 (9.7)

13 (7.0)

 Endocrine therapy alone

37 (9.4)

80 (24.3)

37 (9.2)

76 (23.5)

17 (9.1)

38 (20.4)

 Other anticancer treatment

30 (7.6)

10 (3.0)

46 (11.4)

11 (3.4)

14 (7.5)

7 (3.8)

  1. 1L first-line, AI aromatase inhibitor, CDK4/6 cyclin-dependent kinase 4/6, PAL palbociclib, PSM propensity score matching, sIPTW stabilized inverse probability of treatment weighting.
Back to article page